+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Matrix Metalloproteinase 9 - Pipeline Review, H2 2020

  • ID: 5189129
  • Drug Pipelines
  • October 2020
  • Region: Global
  • 53 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • EA Pharma Co Ltd
  • Elastomics AB
  • Gilead Sciences Inc
  • Iproteos SL
  • MabTrix Ltd
  • Pharmahungary Group
  • MORE
Summary

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Matrix metallopeptidase 9 (MMP-9) is a matrixin that belong to the zinc-metalloproteinases family. It plays an essential role in local proteolysis of the extracellular matrix and in leukocyte migration and bone osteoclastic resorption. MMP9 along with elastase, appears to be a regulatory factor in neutrophil migration across the basement membrane. MMP9 may play an important role in wound repair, angiogenesis and neovascularization.

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) pipeline Target constitutes close to 16 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 7 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 5 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Dermatology, Gastrointestinal, Cardiovascular, Musculoskeletal Disorders, Ophthalmology, Immunology, Infectious Disease, Respiratory and Undisclosed which include indications Neuropathic Pain (Neuralgia), Osteoarthritis Pain, Wounds, Acute Ischemic Stroke, Adenocarcinoma Of The Gastroesophageal Junction, Amyotrophic Lateral Sclerosis, Atopic Dermatitis (Atopic Eczema), Burns, Cancer Pain, Crohn's Disease (Regional Enteritis), Dupuytren Contracture, Epilepsy, Fibrosis, Gastric Cancer, Genital Herpes, Herpes Labialis (Oral Herpes), Herpes Zoster (Shingles), Herpetic Keratitis, Inflammatory Bowel Disease, Keratoconjunctivitis Sicca (Dry Eye), Liver Fibrosis, Lung Adenocarcinoma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Myocardial Infarction, Ocular Pain (Eye Pain), Opium (Opioid) Addiction, Pancreatic Islet Transplant Rejection, Pulmonary Fibrosis, Squamous Non-Small Cell Lung Carcinoma and Unspecified.

The latest report Matrix Metalloproteinase 9 - Pipeline Review, H2 2020, outlays comprehensive information on the Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35)
  • The report reviews Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • EA Pharma Co Ltd
  • Elastomics AB
  • Gilead Sciences Inc
  • Iproteos SL
  • MabTrix Ltd
  • Pharmahungary Group
  • MORE
Introduction
  • Report Coverage
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Overview

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Companies Involved in Therapeutics Development
  • Aquilus Pharmaceuticals Inc
  • EA Pharma Co Ltd
  • Elastomics AB
  • Gilead Sciences Inc
  • Iproteos SL
  • MabTrix Ltd
  • Pharmahungary Group
  • Proteris Biotech Inc
  • Shulov Innovative Science Ltd
  • Translational Sciences Inc
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Drug Profiles

andecaliximab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
AQU-010 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
AQU-118 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
CALY-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Drug to Inhibit Matrix Metalloproteinase 9 for Acute Ischemic Stroke - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
IPRO-003 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Monoclonal Antibody to Inhibit MMP9 for Inflammatory Bowel Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
ND-336 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Protearin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Recombinant MMP-9 Replacement for Liver Fibrosis, Pulmonary Fibrosis, Peyronies Disease, Dupuytren Contracture and Pancreatic Islet Transplant Rejection - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Recombinant Protein to Target MMP-9 for Wounds - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecule to Inhibit Matrix Metalloproteinase 9 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules to Inhibit Carbonic Anhydrases and MMPs for Metastatic Melanoma - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules to Inhibit MMP 2,9 and 13 for Myocardial Infarction - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Vaccine to Target MMP2 and MMP9 for Melanoma - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
ZEP-3 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Dormant Products

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Discontinued Products

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Product Development Milestones
  • Featured News & Press Releases
  • Nov 07, 2018: California research team publishes promising results from peptide based universal cancer vaccine
  • Nov 02, 2016: Abzena Provides Update on GS-5745
  • Sep 21, 2016: Gilead Terminates Phase 2/3 Study of GS-5745 in Patients With Ulcerative Colitis
  • May 13, 2015: Abzena provides an update on the clinical development of one of the humanized antibodies created using its Composite Human Antibody technology
Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact
  • Disclaimer
List of Tables
  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Indications, H2 2020
  • Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Number of Products under Investigation by Universities/Institutes, H2 2020
  • Products under Investigation by Universities/Institutes, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Pipeline by Aquilus Pharmaceuticals Inc, H2 2020
  • Pipeline by EA Pharma Co Ltd, H2 2020
  • Pipeline by Elastomics AB, H2 2020
  • Pipeline by Gilead Sciences Inc, H2 2020
  • Pipeline by Iproteos SL, H2 2020
  • Pipeline by MabTrix Ltd, H2 2020
  • Pipeline by Pharmahungary Group, H2 2020
  • Pipeline by Proteris Biotech Inc, H2 2020
  • Pipeline by Shulov Innovative Science Ltd, H2 2020
  • Pipeline by Translational Sciences Inc, H2 2020
  • Dormant Products, H2 2020
  • Dormant Products, H2 2020 (Contd..1), H2 2020
  • Dormant Products, H2 2020 (Contd..2), H2 2020
  • Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Top 10 Indications, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
Note: Product cover images may vary from those shown
3 of 3
  • Aquilus Pharmaceuticals Inc
  • EA Pharma Co Ltd
  • Elastomics AB
  • Gilead Sciences Inc
  • Iproteos SL
  • MabTrix Ltd
  • Pharmahungary Group
  • Proteris Biotech Inc
  • Shulov Innovative Science Ltd
  • Translational Sciences Inc
Note: Product cover images may vary from those shown
Adroll
adroll